Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study ID
- NCT07651137
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Bacterial Infection
- Donor-derived Infection
- Kidney Transplant
- Kidney Transplant Infection
- Liver Transplant
- Liver Transplant Infection
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible donor-derived infections (infections transmitted from the donor organ). The study will include all liver and kidney transplant recipients with available perfusion fluid culture results from 2021 until the start of the study (retrospective phase) and for two years after study initiation (prospective phase). The study will assess how often high-risk microorganisms are identified in perfusion fluid, whether these findings are associated with complications or infections in recipients, and whether they affect patient outcomes, including mortality.
Key Dates
- First listed
- Jun 16, 2026
- Start date
- Sep 1, 2026
- Status verified
- Jun 2026
- Primary completion
- Feb 28, 2029
- Completion
- Aug 31, 2029
Study Design
- Enrollment
- 1,400 participants (estimated)
Arms
- Arm: Adult patients (≥18 years old) undergoing liver or kidney transplantation at IRCCS AOUBOAdult patients (≥18 years old) undergoing liver or kidney transplantation at IRCCS AOUBO clinical center during the specified study periods
Primary Outcome Measure
To evaluate the clinical impact of high-risk perfusion fluid cultures in terms of infectious complications [ Time Frame: At 30, 90, and 180 days post-transplant ]
Central Contacts
- Matteo Rinaldi, MD+39 051 2143595
- Maddalena Giannella, MD, PhD+39 051 2143199
Related Studies
- Proteogenomic Monitoring and Assessment of Liver Transplant RecipientsRecruiting · Northwestern University · Chicago, Illinois
- Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister DonorPHASE1/PHASE2 · Recruiting · Jeffrey Veale, MD · Los Angeles, California
- Prevalence of BK Viremia in Simultaneous Liver-Kidney TransplantEnrolling By Invitation · Methodist Health System · Dallas, Texas
- The KidneyCARE (Community Access to Research Equity) StudyRecruiting · Tufts Medical Center · Danville, Pennsylvania